Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Bray

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
ACR Open Rheumatology|January 24, 2025
Treatment With Avacopan in Patients With Respiratory Tract Manifestations of Antineutrophil Cytoplasmic Antibody-Associated VasculitisUlrich Specks, Robert F Spiera, Lynn A Fussner, et al.
Atherosclerosis|September 5, 2021
Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational studyMichal Vrablik, Bohumil Seifert, Alexander Parkhomenko, et al.
Kidney International Reports|August 15, 2025
Treatment With Avacopan in ANCA-Associated Vasculitis With Kidney InvolvementDuvuru Geetha, Frank B Cortazar, Annette Bruchfeld, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2012
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind studyGeorge D Demetri, Axel Le Cesne, Sant P Chawla, et al.
HIV/AIDS (Auckland, N.Z.)|August 30, 2012
Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in UgandaSarah Bray, Jillian Gedeon, Ahsan Hadi, et al.
Rheumatology (Oxford, England)|March 4, 2025
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trialDuvuru Geetha, Christian Pagnoux, Sebastian E Sattui, et al.
Journal of the American College of Cardiology|February 15, 2020
Long-Term Evolocumab in Patients With Familial HypercholesterolemiaRaul D Santos, Evan A Stein, G Kees Hovingh, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.
Acta Cardiologica|April 20, 2022
Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational studyPhilippe van de Borne, André Peeters, Luc Janssens, et al.
Journal of the American Heart Association|October 4, 2017
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in HyperlipidemiaPeter P Toth, Gillian Worthy, Shravanthi R Gandra, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
ACR Open Rheumatology|January 24, 2025
Treatment With Avacopan in Patients With Respiratory Tract Manifestations of Antineutrophil Cytoplasmic Antibody-Associated VasculitisUlrich Specks, Robert F Spiera, Lynn A Fussner, et al.
Atherosclerosis|September 5, 2021
Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational studyMichal Vrablik, Bohumil Seifert, Alexander Parkhomenko, et al.
Kidney International Reports|August 15, 2025
Treatment With Avacopan in ANCA-Associated Vasculitis With Kidney InvolvementDuvuru Geetha, Frank B Cortazar, Annette Bruchfeld, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2012
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind studyGeorge D Demetri, Axel Le Cesne, Sant P Chawla, et al.
HIV/AIDS (Auckland, N.Z.)|August 30, 2012
Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in UgandaSarah Bray, Jillian Gedeon, Ahsan Hadi, et al.
Rheumatology (Oxford, England)|March 4, 2025
Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trialDuvuru Geetha, Christian Pagnoux, Sebastian E Sattui, et al.
Journal of the American College of Cardiology|February 15, 2020
Long-Term Evolocumab in Patients With Familial HypercholesterolemiaRaul D Santos, Evan A Stein, G Kees Hovingh, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.
Acta Cardiologica|April 20, 2022
Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational studyPhilippe van de Borne, André Peeters, Luc Janssens, et al.
Journal of the American Heart Association|October 4, 2017
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in HyperlipidemiaPeter P Toth, Gillian Worthy, Shravanthi R Gandra, et al.
Pageof 6